MA49560A - Composés cétoniques bicycliques et leurs procédés d'utilisation - Google Patents

Composés cétoniques bicycliques et leurs procédés d'utilisation

Info

Publication number
MA49560A
MA49560A MA049560A MA49560A MA49560A MA 49560 A MA49560 A MA 49560A MA 049560 A MA049560 A MA 049560A MA 49560 A MA49560 A MA 49560A MA 49560 A MA49560 A MA 49560A
Authority
MA
Morocco
Prior art keywords
bicyclic
processes
ketonic compounds
ketonic
compounds
Prior art date
Application number
MA049560A
Other languages
English (en)
Other versions
MA49560B1 (fr
Inventor
Huifen Chen
Blake Daniels
Gregory Hamilton
Snahel Patel
Craig Stivala
Guiling Zhao
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA49560A publication Critical patent/MA49560A/fr
Publication of MA49560B1 publication Critical patent/MA49560B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA49560A 2017-07-14 2018-07-12 Composés cétoniques bicycliques et leurs procédés d'utilisation MA49560B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762532767P 2017-07-14 2017-07-14
PCT/EP2018/068998 WO2019012063A1 (fr) 2017-07-14 2018-07-12 Composés cétoniques bicycliques et leurs procédés d'utilisation

Publications (2)

Publication Number Publication Date
MA49560A true MA49560A (fr) 2020-05-20
MA49560B1 MA49560B1 (fr) 2024-05-31

Family

ID=62916677

Family Applications (1)

Application Number Title Priority Date Filing Date
MA49560A MA49560B1 (fr) 2017-07-14 2018-07-12 Composés cétoniques bicycliques et leurs procédés d'utilisation

Country Status (30)

Country Link
US (3) US11098058B2 (fr)
EP (2) EP4397309A3 (fr)
JP (2) JP7258843B2 (fr)
KR (2) KR20240065201A (fr)
CN (2) CN119613408A (fr)
AR (1) AR112274A1 (fr)
AU (3) AU2018300043B2 (fr)
BR (1) BR112020000771A2 (fr)
CA (2) CA3185865A1 (fr)
CL (1) CL2020000101A1 (fr)
CO (1) CO2020000134A2 (fr)
CR (1) CR20200002A (fr)
DK (1) DK3652178T3 (fr)
ES (1) ES2973661T3 (fr)
FI (1) FI3652178T3 (fr)
HR (1) HRP20240354T1 (fr)
HU (1) HUE065793T2 (fr)
IL (2) IL294961A (fr)
LT (1) LT3652178T (fr)
MA (1) MA49560B1 (fr)
PE (1) PE20200793A1 (fr)
PH (1) PH12020500105A1 (fr)
PL (1) PL3652178T3 (fr)
PT (1) PT3652178T (fr)
RS (1) RS65308B1 (fr)
SG (1) SG11202000333UA (fr)
SI (1) SI3652178T1 (fr)
TW (1) TWI805595B (fr)
UA (1) UA125448C2 (fr)
WO (1) WO2019012063A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11071721B2 (en) * 2016-12-02 2021-07-27 Genentech, Inc. Bicyclic amide compounds and methods of use thereof
BR112020000771A2 (pt) 2017-07-14 2020-07-14 F. Hoffmann-La Roche Ag compostos de cetona bicíclica e métodos de uso dos mesmos
AR113811A1 (es) 2017-10-31 2020-06-10 Hoffmann La Roche Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos
CN113302193A (zh) 2019-01-11 2021-08-24 豪夫迈·罗氏有限公司 双环吡咯并三唑酮化合物及其使用方法
WO2021198981A1 (fr) 2020-04-01 2021-10-07 Janssen Biopharma, Inc. Composés antiviraux et leurs utilisations
TWI879949B (zh) 2020-04-27 2025-04-11 南韓商奧土擇破利悟股份有限公司 用於ｕｂｒ盒結構域配體之化合物、組成物以及醫藥組成物
IL307250A (en) 2021-04-02 2023-11-01 Hoffmann La Roche Processes for preparing bicyclic ketone compounds
WO2023039795A1 (fr) * 2021-09-16 2023-03-23 维泰瑞隆（北京）生物科技有限公司 Inhibiteur de la kinase rip1 et son utilisation
CA3256884A1 (fr) 2022-05-19 2023-11-23 Merck Sharp & Dohme Llc Inhibiteurs de ripk1 et procédés d'utilisation
AU2024312554A1 (en) * 2023-06-19 2025-12-18 F. Hoffmann-La Roche Ag Process for the preparation of a chiral pyrrolo triazole alcohol

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1620508A1 (de) 1965-07-23 1969-09-18 Thomae Gmbh Dr K Verfahren zur Herstellung neuer 4,5,6,7-Tetrahydrothiazolo-[5,4-c]-pyridine
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3948903A (en) 1972-12-15 1976-04-06 Parke, Davis & Company Substituted N-(1,2-dihydro-2-oxonicotinyl)-cephalexins and -cephaloglycins
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0102324A3 (fr) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipides et composés tensio-actifs en phase aqueuse
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
GB8610530D0 (en) 1986-04-30 1986-06-04 Fbc Ltd Herbicides
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
ATE191853T1 (de) 1992-07-27 2000-05-15 Us Health Zielgerichte liposome zur blut-hirne schranke
US6080772A (en) 1995-06-07 2000-06-27 Sugen, Inc. Thiazole compounds and methods of modulating signal transduction
CA2293400A1 (fr) 1997-06-13 1998-12-17 Gerald Mcmahon Nouveaux composes heteroaryle pour la modulation de la transduction de signaux cellulaires associee aux enzymes proteine tyrosine
WO2001058869A2 (fr) * 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Modulateurs de recepteurs aux cannabinoides, leurs procedes de preparation et utilisations de modulateurs de recepteurs aux cannabinoides pour le traitement de maladies respiratoires et non respiratoires
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
US20020065259A1 (en) 2000-08-30 2002-05-30 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
AU2002322720B2 (en) 2001-07-25 2008-11-13 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
EP1572113B1 (fr) 2002-08-26 2017-05-17 Takeda Pharmaceutical Company Limited Compose modulateur de recepteur de calcium et utilisation associee
JP4995423B2 (ja) 2002-12-03 2012-08-08 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート 物質を血液−脳関門を渡って輸送するための人工低密度リポタンパク質キャリア
JP2006526015A (ja) 2003-05-02 2006-11-16 エラン ファーマシューティカルズ，インコーポレイテッド 炎症疾患治療のためのブラジキニンｂ１受容体アンタゴニストとしての４−ブロモ−５−（２−クロロ−ベンゾイルアミノ）−１ｈ−ピラゾール−３−カルボン酸アミド誘導体および関連化合物
JP2007505142A (ja) 2003-09-10 2007-03-08 セダーズ−シナイ メディカル センター 血液脳関門を通過する薬剤のカリウムチャネル媒介性送達
WO2006114706A1 (fr) 2005-04-26 2006-11-02 Pfizer Limited Derives de triazole utilises comme antagonistes de la vasopressine
EP2083009A1 (fr) 2008-01-22 2009-07-29 Grünenthal GmbH Composés tétrahydroimidazopyridine substitués et leur utilisation en tant que médicament
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
CN101824036A (zh) 2009-03-05 2010-09-08 上海恒瑞医药有限公司 四氢咪唑并[1，5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用
AR077463A1 (es) 2009-07-09 2011-08-31 Irm Llc Derivados de imidazo[1, 2 - a]pirazina y su uso en medicamentos para el tratamiento de enfermedades parasitarias
MX2014005285A (es) 2011-11-03 2014-05-30 Hoffmann La Roche Compuestos biciclicos de piperazina.
CN104271566B (zh) 2012-05-22 2017-05-31 霍夫曼-拉罗奇有限公司 取代的联吡啶胺及其用途
JP6199991B2 (ja) 2013-01-18 2017-09-20 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ３置換ピラゾール及びｄｌｋ阻害剤としての使用
TWI637951B (zh) * 2013-02-15 2018-10-11 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類
JP6523251B2 (ja) 2013-05-01 2019-05-29 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃ−結合ヘテロシクロアルキル置換ピリミジン類及びそれらの用途
AR096151A1 (es) 2013-05-01 2015-12-09 Hoffmann La Roche Compuestos de biheteroarilo y usos de los mismos
CN105473554B (zh) 2013-07-10 2019-08-13 沃泰克斯药物股份有限公司 作为离子通道调节剂的稠合的哌啶酰胺类
MX2016008110A (es) 2013-12-20 2016-08-19 Hoffmann La Roche Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
EA032357B1 (ru) 2014-03-26 2019-05-31 Ф. Хоффманн-Ля Рош Аг Конденсированные [1,4]диазепиновые соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa)
CN106573006A (zh) 2014-08-21 2017-04-19 葛兰素史密斯克莱知识产权发展有限公司 作为药物的rip1激酶抑制剂杂环酰胺
WO2016128908A1 (fr) * 2015-02-12 2016-08-18 Advinus Therapeutics Limited Composés bicycliques, compositions et applications médicinales correspondantes
CN107406462B (zh) 2015-03-09 2020-11-10 豪夫迈·罗氏有限公司 三环dlk抑制剂及其用途
EP3317269B1 (fr) 2015-07-02 2022-09-21 F. Hoffmann-La Roche AG Lactames bicycliques en tant qu'inhibiteurs de la protéine kinase 1 interagissant avec des récepteurs pour le traitment par ex. de maladies inflammatoires
WO2017096301A1 (fr) 2015-12-04 2017-06-08 Denali Therapeutics Inc. Inhibiteurs dérivés d'isoxazolidine de protéine kinase 1 interagissant avec un récepteur (ripk 1)
US10961258B2 (en) 2015-12-21 2021-03-30 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
IL287136B2 (en) 2016-02-05 2023-09-01 Denali Therapeutics Inc Receptor inhibitors - interacting with protein kinase 1
US11071721B2 (en) 2016-12-02 2021-07-27 Genentech, Inc. Bicyclic amide compounds and methods of use thereof
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
WO2018128908A1 (fr) 2017-01-05 2018-07-12 Microsoft Technology Licensing, Llc Redirection de sortie audio
BR112020000771A2 (pt) 2017-07-14 2020-07-14 F. Hoffmann-La Roche Ag compostos de cetona bicíclica e métodos de uso dos mesmos
RU2020114670A (ru) 2017-10-11 2021-11-12 Ф. Хоффманн-Ля Рош Аг Бициклические соединения для применения в качестве ингибиторов rip1 киназы
AR113811A1 (es) 2017-10-31 2020-06-10 Hoffmann La Roche Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos

Also Published As

Publication number Publication date
EP3652178A1 (fr) 2020-05-20
US20210139504A1 (en) 2021-05-13
RU2020106375A (ru) 2021-08-16
KR20200030558A (ko) 2020-03-20
CA3067944A1 (fr) 2019-01-17
EP3652178B1 (fr) 2024-01-24
BR112020000771A2 (pt) 2020-07-14
AU2021204369A1 (en) 2021-07-29
EP4397309A2 (fr) 2024-07-10
IL271981A (en) 2020-02-27
JP7734163B2 (ja) 2025-09-04
US20190100530A1 (en) 2019-04-04
RS65308B1 (sr) 2024-04-30
AU2023203292A1 (en) 2023-06-22
HRP20240354T1 (hr) 2024-06-07
KR20240065201A (ko) 2024-05-14
US11834461B2 (en) 2023-12-05
AR112274A1 (es) 2019-10-09
JP7258843B2 (ja) 2023-04-17
US11098058B2 (en) 2021-08-24
PH12020500105A1 (en) 2020-11-09
JP2023085449A (ja) 2023-06-20
WO2019012063A1 (fr) 2019-01-17
NZ760749A (en) 2024-08-30
HUE065793T2 (hu) 2024-06-28
CO2020000134A2 (es) 2020-01-17
CR20200002A (es) 2020-02-10
ES2973661T3 (es) 2024-06-21
CL2020000101A1 (es) 2020-07-17
JP2020526549A (ja) 2020-08-31
KR102664604B1 (ko) 2024-05-14
CN110914271A (zh) 2020-03-24
CN110914271B (zh) 2024-12-10
AU2018300043A1 (en) 2020-01-16
TW201920149A (zh) 2019-06-01
AU2023203292B2 (en) 2025-01-30
EP4397309A3 (fr) 2024-09-04
MA49560B1 (fr) 2024-05-31
CN119613408A (zh) 2025-03-14
SI3652178T1 (sl) 2024-05-31
IL271981B (en) 2022-09-01
CA3067944C (fr) 2023-03-14
DK3652178T3 (da) 2024-03-25
AU2018300043B2 (en) 2021-04-01
RU2020106375A3 (fr) 2022-03-25
PT3652178T (pt) 2024-03-18
IL294961A (en) 2022-09-01
PE20200793A1 (es) 2020-08-10
TWI805595B (zh) 2023-06-21
UA125448C2 (uk) 2022-03-09
LT3652178T (lt) 2024-04-10
FI3652178T3 (fi) 2024-03-19
US20240300974A1 (en) 2024-09-12
SG11202000333UA (en) 2020-02-27
PL3652178T3 (pl) 2024-05-06
CA3185865A1 (fr) 2019-01-17

Similar Documents

Publication Publication Date Title
EP3504213A4 (fr) Composés amino-pyrrolopyrimidinone et leurs procédés d'utilisation
EP3429635A4 (fr) Composés anti-crispr et leurs procédés d'utilisation
MA49560A (fr) Composés cétoniques bicycliques et leurs procédés d'utilisation
MA43827A (fr) Composés di-nucléotides cycliques et leurs procédés d'utilisation
EP3370715A4 (fr) Composés chimères de ciblage de protéolyse et procédés de préparation et d'utilisation de ceux-ci
EP3665156A4 (fr) Composés, compositions et procédés
EP3380101A4 (fr) Composés inhibiteurs d'eif4-a et procédés associés
MA50063A (fr) Composés, compositions et procédés
MA49861A (fr) Composés de benzoxazépine oxazolidinone et leurs procédés d'utilisation
MA54946A (fr) Procédés et composés
EP3436030A4 (fr) Récepteurs chimériques et leurs procédés d'utilisation
MA42055A (fr) Composés antimicrobiens et procédés de fabrication et d'utilisation de ceux-ci
EP3436048A4 (fr) Néoantigènes et leurs procédés d'utilisation
MA39915A (fr) Composés de pladiénolide pyridine et leurs procédés d'utilisation
MA43389A (fr) Anticorps anti-ox40 et leurs procédés d'utilisation
EP3307762A4 (fr) Variants de cas9 rapporteurs et leurs procédés d'utilisation
EP3368538A4 (fr) Inhibiteurs de la kinase wee 1 et leurs procédés de fabrication et d'utilisation
EP3319610A4 (fr) Oxystérols et leurs procédés d'utilisation
EP3303435A4 (fr) Hydrofluoroléfines et procédés d'utilisation associés
MA47167A (fr) Composés pyrazolopyrimidine et leurs procédés d'utilisation
MA48942A (fr) Composés thérapeutiques, compositions et procédés d'utilisation associés
MA41296A (fr) Procédés de transdifférenciation et procédés d'utilisation de ceux-ci
EP3675847A4 (fr) Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci
EP3526205A4 (fr) Composés thérapeutiques et leurs procédés d'utilisation
EP3468555A4 (fr) Composés antimicrobiens et leurs procédés d'utilisation